Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in aspirin-exacerbated respiratory disease
2017-003119-21Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD), sponsored by Medical University of Vienna. Primary endpoint: Efficacy regarding salicylic acid intolerance after 6 months. Started Sep 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (AERD)
Beyond the preview
Go deeper on 2017-003119-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003119-21.